![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Characterization of Virologic Escape in HCV
Genotype 1 Null Responders Receiving a
Combination of the NS3 Protease Inhibitor
BMS-650032 and NS5A Inhibitor BMS-790052
|
|
|
Reported by Jules Levin
46th EASL Congress, Berlin, Germany
March 30-April 3, 2011
F McPhee, D Hernandez, F Yu, J Ueland, C Wang, H Huang,
S Levine, D Gardiner, R Fridell, M Gao
EASL: Quadruple Therapy With BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 Weeks Results in 100% SVR12 in HCV Genotype 1 Null Responders: "HCV infection can be cured without interferon & ribavirin: 2 orals BMS790052+BMS650032" - (04/02/11)
![EASL1.gif](../images/040511/040511-1/EASL1.gif)
![EASL2.gif](../images/040511/040511-1/EASL2.gif)
![EASL3.gif](../images/040511/040511-1/EASL3.gif)
![EASL4.gif](../images/040511/040511-1/EASL4.gif)
![EASL5.gif](../images/040511/040511-1/EASL5.gif)
![EASL6.gif](../images/040511/040511-1/EASL6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|